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Abstract
Background: Perivascular epithelioid cell tumor (PEComa), other than angiomyolipoma (AML),
clear cell sugar tumor (CCST), and lymphangioleiomyomatosis (LAM), is a very rare mesenchymal
tumor with an unpredictable natural history. The uterus is the most prevalent reported site of
involvement of PEComa-not otherwise specified (PEComa-NOS). To the best of our knowledge,
about 100 PEComa-NOS have been reported in the English Language medical literature, of which
38 were uterine PEComa-NOS. These reported cases of uterine PEComa-NOS have usually shown
clinically benign behavior, but 13 tumors, three of them associated with tuberous sclerosis complex
(TSC), exhibited local aggressive behavior and four of them showed distant metastases.
Case presentation: We report the case of a 59-year-old woman, who presented with renal and
pulmonary lesions seven years after the initial diagnosis of uterine leiomyosarcoma. Left
nephrectomy and right middle lobe wedge resection were performed. Histological and
immunohistochemical analysis of the renal and pulmonary lesions, in addition to retrospective re-
evaluation of the previous uterine tumor, led to the final diagnosis of malignant uterine PEComa
with late renal and pulmonary metastases. All three lesions had the typical histological appearance
of PEComa-NOS showing a biphasic growth pattern with continuous transition between spindle
cells and epithelioid cells, often arranged around vascular spaces. Immunohistochemically, the
tumor cells of both phenotypes in all three lesions stained for melanocytic (HMB-45 and Melan-A/
MART-1) and myoid (desmin, smooth muscle actin, and muscle-specific actin/all muscle actin/HHF-
35) markers.
Conclusion: The findings indicate that despite the small number of reported cases, PEComas-
NOS should be considered tumors of uncertain malignant potential, and metastases to other
organs might become evident even several years after the primary diagnosis.
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Background
The World Health Organization defines perivascular epi-
thelioid cell tumors (PEComas) as "mesenchymal tumors
composed of histologically and immunohistochemically
distinctive perivascular epithelioid cells (PECs)" [1]. In
1991, Pea and colleagues [2] first noted this unusual cell
in both angiomyolipoma (AML) and clear cell sugar
tumor (CCST) of the lung. One year later, Bonetti and col-
leagues [3] proposed a cellular link between AML, CCST,
and lymphangioleiomyomatosis (LAM), their association
with tuberous sclerosis complex (TSC), and advanced the
concept of a family of neoplasms composed of this dis-
tinctive cell which was "immunoreactive with melano-
cytic markers, and exhibit an epithelioid appearance, a
clear-acidophilic cytoplasm, and a perivascular distribu-
tion". In 1996, Zamboni et al [4] reported the first case of
pancreatic CCST and suggested the name PEComa for
these neoplasms composed of a pure proliferation of
PECs. There is no known normal cellular counterpart to
this PEC, and a precursor lesion for PEComas has not
been described [1]. Subsequently, the PEComa family of
tumors has grown to include AML, CCST, LAM, and a
number of rare unusual visceral, intraabdominal, soft tis-
sue and bone tumors, which have been described under a
variety of names, including "clear cell myomelanocytic
tumor (CCMMT) of the falciform ligament/ligamentum
teres", "abdominopelvic sarcoma of perivascular epithe-
lioid cells", and "primary extrapulmonary clear cell sugar
tumor", among others. This latter group of rare, morpho-
logically and immunophenotypically similar tumors aris-
ing at a variety of visceral (commonly gastrointestinal,
gynecological and genitourinary) and soft tissue (com-
monly retroperitoneal, abdominopelvic and cutaneous)
sites have been collectively termed non-AML, non-LAM,
non-CCST PEComas; or PEComas other than AML, LAM
or CCST; or PEComas-not otherwise specified (PEComas-
NOS) [1]. Generally, CCMMT is now not considered a dis-
tinct entity, but rather fall within the morphological spec-
trum of PEComas-NOS [1].
To the best of our knowledge, about 100 PEComas-NOS
have been reported in the English Language medical liter-
ature, of which 38 were uterine PEComas-NOS [1,5-17].
These 38 reported cases of uterine PEComas-NOS have
usually shown clinically benign behavior, but thirteen
tumors exhibited locally aggressive behavior [5-9]. Three
of these thirteen locally aggressive uterine PEComa-NOS
were associated with TSC [5,6], whilst four of them
showed distant metastases to liver, lungs, intestines, bone
and lymph nodes up to seven years after resection of the
uterine tumors [5,7,9]. Although there is a strong associa-
tion between TSC, AML, LAM and CCST; this association
is much less clear for the rarer PEComas-NOS [1]. Since
relatively few cases of malignant PEComa have been
reported and the duration of follow-up relatively short in
the reported cases of PEComa, firm criteria for malignancy
have yet to be established. However, a recent review report
suggested criteria for malignancy including a size of >8.0
cm, mitotic count of >1 per 50 high-power fields (HPFs)
and necrosis; and these three criteria helped to stratify
PEComas into benign, uncertain malignant potential, and
malignant [8]. Unfortunately, until more cases of this rare
tumor are evaluated in a systematic fashion, firm criteria
for malignancy remain uncertain. We report herein the
case of a 59-year-old woman who presented with renal
and pulmonary lesions seven years after the initial diag-
nosis of uterine leiomyosarcoma, but histological and
immunohistochemical analysis of the renal, pulmonary
and previous uterine lesions led to the final diagnosis of
malignant uterine PEComa-NOS with late renal and pul-
monary metastases.
Case presentation
A 59-year-old woman with a past medical history of hys-
terectomy and bilateral salpingo-ophrectomy for uterine
leiomyosarcoma (American Joint Commission on Cancer
Staging; AJCC T1c N0 M0; diagnosed at an outside institu-
tion) seven years prior presented to our institution for her
regular periodic computed tomography (CT) scans of the
abdomen, chest and pelvis at 6-month intervals as tumor
follow-up investigations. These CT scans revealed several
coalescing rim-enhancing nodules (altogether measuring
6.0 cm) in the upper and middle poles of her left kidney
and a solitary rim-enhancing nodule (measuring 1.5 cm)
in her right middle lobe of lung, which were absent on her
previous CT scans six months earlier. The clinical impres-
sion was metastasis from her previous uterine leiomyosa-
rcoma. No additional nodules were identified in the
brain, gastrointestinal (GI) tract, liver, spleen, pancreas,
bladder and bones on subsequent staging magnetic reso-
nance imaging (MRI) of the brain, abdomen, chest and
pelvis, and positron emission tomography (PET) scan.
The patient did not have any stigmata or family history of
TSC, and had no history of melanoma. General physical
examination was unremarkable. Her hemogram, urine
and blood biochemical analyses were within normal
ranges.
A left radical nephrectomy and video-assisted thoraco-
scopic surgical wedge resection of the right middle lobe
solitary nodule were performed. Grossly, her resected left
kidney revealed a sharply demarcated and lobulated firm
gray-tan nodular tumor (7.5 × 6.2 × 5.4 cm) occupying the
upper and middle poles, and showed focally hemorrhagic
areas on cut surface (Figure 1A). The interface between
tumor and uninvolved kidney was sharp (Figure 1A). A
3.0 cm tan tumor thrombus protruded from the renal vein
resection margin, whilst the renal artery and ureter resec-
tion margins were grossly free of tumor. The tumor grossly
infiltrated into the renal sinus and extended broadly to,Diagnostic Pathology 2007, 2:45 http://www.diagnosticpathology.org/content/2/1/45
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but not through, both the anterior and posterior renal
capsules. Gross infiltration of tumor into the perinephric
adipose tissue was absent. Her wedge-resected right mid-
dle lobe of lung revealed a sharply demarcated firm gray-
tan nodule (2.3 × 2.2 × 2.0 cm) with focally hemorrhagic
overlying pleura. The cut surface of the tumor was focally
hemorrhagic. The tumor extends to, but not through the
overlying pleura, and was at least 0.5 cm from the nearest
stapled resection margin.
Histologically, the renal tumor was biphasic and com-
posed mainly of medium to large epithelioid cells and
focal areas of spindle/elongated cells around numerous
small blood vessels (Figures 1B & 1C). The medium to
large epithelioid neoplastic cells were arranged in solid
nests or cords, and had well-defined cytoplasmic borders
with abundant cytoplasm that varied from eosinophilic
and granular to clear (Figure 1C). The nuclei of the epithe-
lioid cells were mainly round, centrally located, and vesic-
ular, with moderate-to-severe pleomorphism and
hyperchromatism (Figures 1C &1D). Extensive cellular
atypia, including bizarre multinucleated giant cells with
large nuclei and nucleoli, was present (Figure 1D). Con-
spicuous nucleoli and mitoses were frequently present
(Figure 1D). Mitotic count for the renal tumor was high
(60 per 50 HPFs). There was microscopic evidence of
tumor invasion of the renal sinus and the renal vein, and
extensive neoplastic cell invasion of smaller veins. The
adrenal gland was unremarkable and was not invaded by
tumor, and the non-neoplastic kidney revealed mild
nephrosclerosis.
Microscopic examination of the pulmonary tumor (not
shown) exhibited the same morphological features as the
renal tumor described above (Figures 1B–1D). The inter-
face between tumor and uninvolved lung was sharp, and
several foci of hemorrhage and necrosis were present.
Mitotic count for the pulmonary tumor was high (45 per
50 HPFs). The non-neoplastic lung tissue was unremarka-
ble (not shown). Based on her history of status post hys-
terectomy for uterine leiomyosarcoma (diagnosed at an
outside institution) seven years prior and the biphasic his-
tologic appearance of spindle and epithelioid cells (with
clear cell areas) with prominent perivascular distribution
of neoplastic cells in both the renal and pulmonary
tumors, a diagnosis of malignant uterine PEComa with
renal and pulmonary metastases was considered. The
pathology report, original hematoxylin-eosin (H&E)
slides, and formalin-fixed paraffin embedded blocks of
the prior uterine tumor were requested from the outside
institution. The original H&E slides and new H&E slides
re-cut from the paraffin blocks were evaluated, and sections
from all three lesions (uterine, renal and pulmonary) were
concurrently subjected to immunohistochemical analysis.
The pathology report from the outside institution indicated
that the prior uterine tumor diagnosed as uterine leiomy-
osarcoma measured 6.0 cm in its greatest dimension, with
a pathologic TMN staging of pT1c N0 M0. Microscopic
examination of the previous uterine tumor (not shown)
exhibited the same morphological features as both the
pulmonary (not shown) and renal (Figures 1B–1D)
tumors described above.
Immunohistochemically, both the epithelioid and spin-
dle neoplastic cells of the renal tumor were strong and dif-
fusely (>80% of the neoplastic cells) positive for desmin
(cytoplasmic and membranous) {Ventana, Tucson, Ariz}
[Figure 2A], HMB-45 (cytoplasmic) {Ventana} [Figure
2B], Melan-A/MART-1 (cytoplasmic) {BioCare Medical,
Walnut Creek, CA}, smooth muscle actin (cytoplasmic
and membranous) {Dako, Carpinteria, CA}, muscle-spe-
cific actin/all muscle actin/HHF-35 (cytoplasmic and
membranous) {Dako} [not shown]. The estrogen recep-
tor (ER) {Ventana} [Figure 2C] and progesterone receptor
(PR) {Ventana} [Figure 2D] immunostains showed
strong nuclear reactivity in 60–80% and 30–50% of
tumor cells, respectively. The renal tumor cells were strong
and diffusely (>80% of the neoplastic cells) positive for
BCL-2 (cytoplasmic and membranous) {Ventana} [Figure
(A) Sharply demarcated gray-tan nodular tumor occupying  the upper and middle poles with focally hemorrhagic areas  on cut surface (Gross) Figure 1
(A) Sharply demarcated gray-tan nodular tumor occupying 
the upper and middle poles with focally hemorrhagic areas 
on cut surface (Gross). (B) Biphasic renal tumor composed 
mainly of medium to large epithelioid cells and focal areas of 
spindle cells around numerous small blood vessels (H&E, 
Original magnification ×100). (C) Perivascular epithelioid 
cells arranged in solid nests or cords with well-defined cyto-
plasmic borders and abundant cytoplasm that varied from 
eosinophilic and granular to clear (H&E, Original magnifica-
tion ×400). (D) Moderate-to-severe nuclei pleomorphism 
and hyperchromatism with bizarre multinucleated giant cells 
and mitoses (H&E, Original magnification ×400).Diagnostic Pathology 2007, 2:45 http://www.diagnosticpathology.org/content/2/1/45
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3A], CD99 (membranous) {Ventana} [Figure 3B], and
cyclin D1 (nuclear) {Ventana} [not shown]. A prolifera-
tive index of 70% was noted with Ki67 immunostaining
(nuclear) {Ventana} [Figure 3C]. The tumor cells showed
focal (<20% of the neoplastic cells), but strong, immuno-
reactivity for c-kit/CD117 (membranous) {Ventana},
vimentin (cytoplasmic and membranous) {Ventana},
epithelial membrane antigen (EMA) {cytoplasmic and
membranous} [Ventana], and CD10 (membranous)
{Ventana} [not shown]. The renal neoplastic cells failed
to stain with antibodies against renal cell carcinoma
marker (RCC) {Ventana} [Figure 3D], S-100 protein
(Ventana), chromogranin (Ventana), cytokeratins (AE1/
AE3, 8/18, 7/20) {Ventana}, CD34 (Ventana), and myo-
genin (Ventana) {not shown}. The immunoprofile of the
pulmonary (not shown) and uterine (not shown) tumors
were identical to that of the renal tumor described above
(Figures 2A–2D & Figures 3A–3D). For all the three
tumors in general, staining for the melanocytic markers
(HMB-45 and Melan-A) were more intense in the epithe-
lioid cells compared to the spindle cells. Staining for the
myoid markers (desmin, smooth muscle actin, and mus-
cle-specific actin) were variable in the cytoplasm and
more prominent adjacent to the cytoplasmic membrane,
and more intense in the spindle cells compared to the epi-
thelioid cells. Positive controls were used for all markers
as follows: HMB-45 and Melan-A – melanoma; RCC –
renal cell carcinoma; S100 – schwannoma; desmin,
smooth muscle actin, muscle-specific actin, and myo-
genin – GI smooth muscle; CD117 – GI mast cells and
Cajal cells; cytokeratins – GI epithelial tissue; vimentin –
GI mesenchymal tissue; and CD34 – tonsillar endothelial
tissue. Slides stained omitting the primary antibody were
used as negative controls.
On the basis of the above histopathological and immuno-
histochemical features, a definitive diagnosis of malig-
nant uterine PEComa with late renal and pulmonary
metastases was rendered. The patient elected not to have
any adjuvant chemotherapy or radiotherapy. Five follow-
up CT scans of the brain, abdomen, chest and pelvis, and
PET scans performed at 3-month intervals after surgery
revealed no nodules. She is alive with no evidence of local
recurrence or distant metastasis after 15 months of follow-
up, and scheduled to have regular periodic CT scans of the
abdomen, chest and pelvis at 3-month intervals as her
tumor follow-up plan.
Discussion
In this report, we describe a case of unusual epithelioid
tumors in the kidney and the lung seven years after the ini-
tial diagnosis of uterine leiomyosarcoma, with pathologi-
cal and immunohistochemical features entirely compatible
Immunohistochemical staining of renal tumor Figure 2
Immunohistochemical staining of renal tumor. (A) Both epi-
thelioid and spindle cells were strong and diffusely positive 
for desmin (Immunoperoxidase, Original magnification 
×200). (B) Both epithelioid and spindle cells were strong and 
diffusely positive for HMB-45 (Immunoperoxidase, Original 
magnification ×200). (C) Estrogen receptor (ER) immunos-
taining showed strong and diffuse nuclear reactivity in tumor 
cells (Immunoperoxidase, Original magnification ×200). (D) 
Progesterone receptor (PR) immunostaining showed strong 
and moderate nuclear reactivity in tumor cells (Immunoper-
oxidase, Original magnification ×200).
Immunohistochemical staining of renal tumor Figure 3
Immunohistochemical staining of renal tumor. (A) Tumor 
cells showed strong and diffusely reactivity for BCL-2 (Immu-
noperoxidase, Original magnification ×200). (B) Tumor cells 
showed strong and diffusely reactivity for CD99 (Immu-
noperoxidase, Original magnification ×200). (C) Ki67 immu-
nostaining showed a proliferative index of 70% 
(Immunoperoxidase, Original magnification ×200). (D) 
Tumor cells showed negative reactivity for renal cell carci-
noma marker (RCC) (Immunoperoxidase, Original magnifica-
tion ×200).Diagnostic Pathology 2007, 2:45 http://www.diagnosticpathology.org/content/2/1/45
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with those of a PEComa. PEComas are characterized by
epithelioid to spindle cells with eosinophilic to clear cyto-
plasm, an intimate relationship with blood vessels, and
demonstrate positive immunostaining for markers of
both melanocytic (HMB45, Melan-A, tyrosinase, micro-
phthalmia transcription factor) and myoid (desmin,
smooth muscle actin, muscle-specific actin, caldesmon,
calponin) differentiation [1]. PEComas-NOS have now
been reported in almost every body site and the growing
list of reported sites include gynecological, genitourinary,
gastrointestinal, extremities and the skin, as well as single
reports in the heart, breast, oral cavity, orbit, and skull
base [1,5-17]. The uterus is the most prevalent reported
site of involvement of PEComa-NOS (accounting for 38
out of about 100 reported cases). The other common sites
are the gastrointestinal tract, genitourinary tract and retro-
peritoneum, whilst rare sites include somatic soft tissue,
skin and bone. Almost all the reported non-uterine PECo-
mas-NOS have been in women [1,5-17]. The vast majority
of PEComas-NOS have been described in females (as in
the case herein presented) [1,5-17], and therefore hor-
mones may play a role in their pathogenesis and/or phe-
notypic cellular manifestations. Estrogen receptor (ER)
and progesterone receptor (PR) expression, that have been
reported primarily in the spindle cell component of
PEComas [5,10], may play a role in the development of
this morphologic pattern. The case herein presented
showed moderate-to-strong positive nuclear staining for
both ER and PR in both the spindle and epithelioid cell
components of all three lesions (uterine, renal and pul-
monary), although the ER staining was always more
intense than PR staining.
PEComas are of interest primarily because of their immu-
noreactivity with melanocytic and myoid markers. They
are also almost always negative for S-100 protein and
cytokeratins. Folpe and colleagues [8] recently reviewed
all reported cases of PEComa up to 2005 (61 cases). In
their review, 100% were HMB-45 positive, 59% were
smooth muscle actin positive, 41% were Melan-A posi-
tive, 33% were CD117 positive, 31% were desmin posi-
tive, 11% were S-100 positive, and 0% was cytokeratin
positive. Therefore, nearly all PEComas are immunoreac-
tive for HMB-45 and/or Melan-A, and many are positive
for smooth muscle actin, whereas desmin staining
appears to be somewhat less common. Elongated spindle
cells in PEComas are characterized by prominent smooth
muscle-specific filaments, while the epithelioid compo-
nent does not usually contain high numbers of such fila-
ments [8]. The case herein presented showed strong and
diffuse staining for both HMB-45 and MelanA in both the
spindle and epithelioid cell components of all three
lesions (uterine, renal and pulmonary), with more intense
staining in the epithelioid cells compared to the spindle
cells. In the present case, staining for muscle-specific actin,
smooth muscle actin, and desmin was more evident in the
area adjacent to the cytoplasmic membrane, with more
intense staining in the spindle cells compared to the epi-
thelioid cells.
Not unexpectedly, the uterine tumor of the case herein
presented was initially misdiagnosed as a uterine leiomy-
osarcoma at an outside institution seven years prior. Myo-
melanocytic marker expression was found to be
prominent in both components of all the three lesions in
the case herein presented. Controversy exists regarding the
minimum criteria for the diagnosis of malignant PEComa
[18,19]. In studies of uterine tumors demonstrating epi-
thelioid morphology, clear cell areas and HMB-45 positiv-
ity, these authors [18,19] argued that these lesions
represented epithelioid smooth muscle tumors with focal
melanocytic differentiation and not PEComas. This view
was based largely on the fact that the tumors looked like
classic leiomyosarcomas with spindled and epithelioid
areas, and stained with desmin. Nevertheless, these
authors [18,19] still advocated performing immunohisto-
chemistry for HMB-45 in all uterine epithelioid smooth
muscle tumors, in order to identify patients who should
be investigated for TSC. It is also noteworthy that only
focal HMB-45 staining was seen in their cases, unlike the
diffuse expression in the case herein presented and nearly
all the reported cases of uterine PEComa [1,5-11]. Addi-
tionally, 31% of PEComas showed at least focal desmin
staining in a recent review of all reported cases up to 2005
(61 cases) [8], and therefore desmin staining of uterine
epithelioid tumors with clear cell areas and HMB-45 pos-
itivity does not exclude the diagnosis of PEComa. We are
therefore of the view that tumors with diffuse myo-
melanocytic differentiation should be regarded as being
related to the PEComa family irrespective of site of origin
or desmin positivity, and that it is the characteristic mor-
phology and immunophenotype that warrants separating
these tumors from classic leiomyosarcoma that exhibit
only muscle differentiation. However the clinicopatho-
logical significance of HMB-45 positivity in uterine epi-
thelioid smooth muscle tumors is not known.
In addition to epithelioid smooth muscle tumors (epithe-
lioid leiomyosarcoma and epithelioid leiomyoma), the
other important differential diagnosis of PEComa include
malignant melanoma, clear cell sarcoma of tendon and
aponeuroeses (melanoma of the soft parts), alveolar soft
part sarcoma, endometrial stromal sarcoma with clear cell
features, uterine tumor resembling sex cord tumor, carci-
noma (especially renal cell and adrenocortical carci-
noma), paraganglioma, angiomyolipoma, and any other
tumor with focal or prominent clear cell change. Malig-
nant melanoma and clear cell sarcoma of tendon and
aponeuroeses can be differentiated from PEComas based
on S-100 positivity; however, up to 11% of PEComasDiagnostic Pathology 2007, 2:45 http://www.diagnosticpathology.org/content/2/1/45
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express S-100 as well [8]. The additional important fea-
tures for the diagnosis of PEComa in this context include
negative history for melanoma, visceral location of tumor,
perivascular accentuation of tumor cells, immunoreactiv-
ity for myoid markers (smooth muscle actin, muscle-spe-
cific actin, and desmin), and absence of the t(12:22)
translocation. Although S-100 negative melanomas have
rarely been described, tumors with S-100 negativity,
strong and diffuse melanocytic marker positivity, and
actin immunoreactivity should be designated as PEComas
based on morphology and immunophenotype. Pitfalls in
the diagnosis of PEComas include aberrant staining of
cells with melanocytic markers. However, diffuse and
multiple melanocytic marker expression is highly reliable
for melanocytic differentiation. Focal or weak positivity
can be disregarded, however, and do not warrant the diag-
nosis of PEComa. The case herein presented was strong
and diffusely positive with at least two melanocytic mark-
ers (HMB45 and Melan-A), which is not a finding in other
sarcomas. Angiomyolipoma can be ruled out because the
present case lacked lipomatous elements and showed a
biphasic cellular population. However, PEComa and
monophasic epithelioid angiomyolipoma are probably
very closely related, if not the same entity. Endometrial
stromal sarcoma and uterine tumor resembling sex cord
tumor can be ruled out because of the presence of promi-
nent perivascular accentuation of tumor cells and diffuse,
rather than focal, positive staining of HMB-45 in
PEComa. PEComa can be distinguished from paragangli-
oma in that the former is negative for chromogranin A,
synaptophysin, and S-100 protein, and the latter shows
more organoid growth. The expression of melanocytic
markers (HMB-45 and MART-1/Melan-A) and the lack of
immunoreactivity for cytokeratins and RCC marker argue
against the diagnosis of carcinoma.
Clinically, most PEComas follow a benign course [1].
Malignant PEComas-NOS are being increasingly reported,
several originating in the uterus and others arising in the
jejunum, ileum, prostate, pelvis, skull base, broad liga-
ment and somatic soft tissue [1,5-17]. Since relatively few
malignant PEComas have been reported, firm criteria for
malignancy have yet to be established. However, Folpe
and colleagues [8] recently suggested criteria for malig-
nancy including a size of >8.0 cm, mitotic count of >1 per
50 high power fields (HPFs) and necrosis, with benign,
uncertain malignant potential and malignant categories
based on the presence of none, 1 or ≥ 2 of these three cri-
teria, respectively. Infiltrative growth or edges, marked
hypercellularity and marked nuclear pleomorphism/aty-
pia may be secondary features suggesting aggressive
behaviour or malignancy [1,8,11]. A Ki-67 labeling index
of 5% of neoplastic cells has been observed in a uterine
PEComa that have behaved aggressively [7]. In the case
herein presented, the size of the primary uterine tumor
seven years prior was <8 cm, mitotic count was >1 per 50
HPFs and necrosis was absent. Retrospectively, this uter-
ine tumor would be categorized as of uncertain malignant
potential according to the above suggested criteria. Addi-
tionally, the uterine tumor showed all the three secondary
features suggestive of aggressive behaviour or malignancy.
Furthermore, the Ki-67 labeling index was greater than
5% in the uterine tumor (also in the renal and pulmonary
metastases), and thus the uterine tumor was destined to
behave aggressively, which it did seven years later.
Dimmler and colleagues have also reported late pulmo-
nary metastases occurring seven years after the diagnosis
of a case of uterine PEComa [7]. Therefore, metastatic
spread of PEComas may, in some cases, be a late compli-
cation, presenting after many years. This highlights both
the need for criteria that more accurately predict the
behavior of PEComas and the need for long-term follow-
up of patients with PEComas, as widespread metastases
may present as a late complication.
Optimal treatment for PEComas is not well established at
this time. Currently, surgery is the mainstay of treatment
for primary PEComa at presentation as well as for local
recurrences and metastases, with the aim of obtaining
clear resection margins. The role of adjuvant therapy
remains unclear. Metastases have been successfully man-
aged by resection alone [7]. Primary excision is usually
curative, as most PEComas are benign. However, locally
advanced or metastatic disease portends a poor prognosis
and treatment strategies incorporating surgery, radiother-
apy and chemotherapy have been reported [20]. Given the
uncertainty of PEComa tumor biology, adjuvant thera-
pies, including chemotherapy and immunotherapy, may
be considered for patients with locally advanced or meta-
static PEComa.
Conclusion
We have described a case of malignant PEComa-NOS of
the uterus with late renal and pulmonary metastases seven
years after hysterectomy. Malignant PEComa should be
considered in the light microscopic differential diagnosis
for all pleomorphic sarcomas. PEComas-NOS show a
marked female predominance, are rare but anatomically
ubiquitous mesenchymal tumors that are composed of
nests and sheets of usually epithelioid but occasionally
spindled cells with clear to granular eosinophilic cyto-
plasm and a focal association with vascular spaces. They
usually show immunoreactivity for both melanocytic
(HMB-45 and/or Melan-A/Mart-1) and myoid/muscle-
specific (actin and/or desmin) markers, which are useful
for confirming the diagnosis. The mainstay of treatment is
wide excision. Though most PEComas are benign, a sub-
set behaves in a malignant fashion; size >8 cm, high
mitotic index, presence of necrosis, marked cytological
atypia, and/or infiltrative growth pattern may be associ-Publish with BioMed Central    and   every 
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ated with malignant behavior. However, since relatively
few malignant PEComas have been reported, firm criteria
for malignancy have yet to be established and the identity
of the normal PEC remains elusive. Further studies on
additional cases with longer clinical follow-up would be
necessary to accurately predict the biologic behavior of
these distinctive tumors. Finally, because PEComas can
behave in an aggressive manner, careful follow up is war-
ranted.
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